Search

Your search keyword '"Arezoo Karimi Moghaddam"' showing total 5 results
Start Over Author "Arezoo Karimi Moghaddam"
5 results on '"Arezoo Karimi Moghaddam"'

1. Effectiveness of isometric exercises on disability and pain of cervical spondylosis: a randomized controlled trial

Author

Alireza Sadeghi, Mina Rostami, Sahand Ameri, Arezoo Karimi Moghaddam, Zhaleh Karimi Moghaddam, and Alireza Zeraatchi

Subjects
Isometric exercise, Cervical spondylosis, Neck pain, Disability, Sports medicine, RC1200-1245
Abstract

Abstract Background Neck pain and disability is a significant public health problem with only very few evidence-based treatment option. The aim of this study was to evaluate the effect of isometric exercise on pain and disability of cervical spondylosis. Methods Twenty four patients with cervical osteoarthritis and neck pain (22 females and 2 males; mean age, 46.70 ± 13.71 years) were recruited and randomly allocated into 2 arms: neck isometric exercises (n = 12) and conservative management without exercise (n = 12). The Neck Disability Index (NDI) and Neck Pain and Disability Scale (NPAD) were used to assess participants at baseline and after 4 weeks. Results Basic characteristics, NDI score and NPAD score were not significantly different between groups at baseline. The exercise arm demonstrated significantly lower scores regarding NDI (mean, 17.41 vs. 25.58; P-value = 0.035) and NPAD (mean, 25.33 vs. 66.67; P

Published
2022
Full Text
View/download PDF

2. Half-dose photodynamic therapy for chronic central serous chorioretinopathy

Author

Masood Naseripour, Khalil Ghasemi Falavarjani, Ahad Sedaghat, Arezoo Karimi Moghaddam, Sadaf Nasserisina, and Sayyed Amirpooya Alemzadeh

Subjects
Optical Coherence Tomography, Central Serous Chorioretinopathy, Photodynamic Therapy, Ophthalmology, RE1-994
Abstract

Purpose: To report the outcomes of half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC). Methods: A chart review of patients with chronic CSC who had received half-dose verteporfin PDT (3 mg/m2) was performed. The main outcome measures were resolution of subretinal fluid and best corrected visual acuity (BCVA). Results: Fifty-three eyes of 51 patients with mean age of 45.01 ± 8.9 years were studied. Three, 6 and 12 months after half-dose PDT, subretinal fluid was completely resolved in 51 eyes (96.2%). In 2 eyes (one patient), subretinal fluid decreased at 3 months but one year later, an increase in subretinal fluid was detected on optical coherence tomography (OCT) which completely resolved following additional PDT. Another patient with recurrence of subretinal fluid rejected further treatment. Mean baseline central subfield thickness was 385 ± 113.0 μm which was decreased to 235 ± 39.7, 247 ± 49.7, and 244 ± 49.52 μm after 3, 6 and 12 months, respectively (all P-values < 0.001). Mean BCVA was 0.33 ± 0.27 LogMAR before PDT and 0.11 ± 0.18, 0.11 ± 0.17, 0.17 ± 0.26 and 0.10 ± 0.23 LogMAR, 3, 6 and 12 months and at final visit (up to 60 months) after PDT, respectively (all P-values < 0.001). Improvement ≥2 lines in BCVA occurred in 20 eyes (37.7%). Statistically significant correlations were found between improvement in BCVA and baseline BCVA, baseline central subfield thickness and central subfield thickness after resorption of subretinal fluid (P < 0.001, P= 0.04 and P= 0.01, respectively). No complications attributed to PDT were observed. Conclusion: Half-dose PDT is effective for treatment of patients with chronic CSC.

Published
2016
Full Text
View/download PDF

4. Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Author

Ahad Sedaghat, Arezoo Karimi Moghaddam, Masood Naseripour, Khalil Ghasemi Falavarjani, Sadaf Nasserisina, and Sayyed Amirpooya Alemzadeh

Subjects
medicine.medical_specialty, genetic structures, medicine.medical_treatment, Photodynamic therapy, 01 natural sciences, Chronic central serous chorioretinopathy, 03 medical and health sciences, 0302 clinical medicine, lcsh:Ophthalmology, Chart review, Ophthalmology, medicine, In patient, Optical Coherence Tomography, Central Serous Chorioretinopathy, Photodynamic Therapy, business.industry, Outcome measures, Mean age, Verteporfin, eye diseases, 0104 chemical sciences, Surgery, 010404 medicinal & biomolecular chemistry, lcsh:RE1-994, 030221 ophthalmology & optometry, Original Article, Subretinal fluid, business, medicine.drug
Abstract

Purpose: To report the outcomes of half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC). Methods: A chart review of patients with chronic CSC who had received half-dose verteporfin PDT (3 mg/m2) was performed. The main outcome measures were resolution of subretinal fluid and best corrected visual acuity (BCVA). Results: Fifty-three eyes of 51 patients with mean age of 45.01 ± 8.9 years were studied. Three, 6 and 12 months after half-dose PDT, subretinal fluid was completely resolved in 51 eyes (96.2%). In 2 eyes (one patient), subretinal fluid decreased at 3 months but one year later, an increase in subretinal fluid was detected on optical coherence tomography (OCT) which completely resolved following additional PDT. Another patient with recurrence of subretinal fluid rejected further treatment. Mean baseline central subfield thickness was 385 ± 113.0 μm which was decreased to 235 ± 39.7, 247 ± 49.7, and 244 ± 49.52 μm after 3, 6 and 12 months, respectively (all P-values < 0.001). Mean BCVA was 0.33 ± 0.27 LogMAR before PDT and 0.11 ± 0.18, 0.11 ± 0.17, 0.17 ± 0.26 and 0.10 ± 0.23 LogMAR, 3, 6 and 12 months and at final visit (up to 60 months) after PDT, respectively (all P-values < 0.001). Improvement ≥2 lines in BCVA occurred in 20 eyes (37.7%). Statistically significant correlations were found between improvement in BCVA and baseline BCVA, baseline central subfield thickness and central subfield thickness after resorption of subretinal fluid (P < 0.001, P= 0.04 and P= 0.01, respectively). No complications attributed to PDT were observed. Conclusion: Half-dose PDT is effective for treatment of patients with chronic CSC.

Published
2016

5. Posterior sub-tenon’s bevacizumab injection in diabetic macular edema; a pilot study

Author

Khalil Ghasemi Falavarjani, Nasser Karimi, Mehdi Modarres, Joobin Khadamy, and Arezoo Karimi Moghaddam

Subjects
medicine.medical_specialty, genetic structures, Bevacizumab, Diabetic macular edema, chemistry.chemical_compound, Diabetic retinopathy, Ophthalmology, Medicine, Macular edema, Bevacizumab Injection, business.industry, Significant difference, Sub-tenon’s injection, Retinal, medicine.disease, eye diseases, chemistry, Original Article, sense organs, business, Complication, medicine.drug
Abstract

Purpose To evaluate the short-term results of sub-tenon's injection of bevacizumab in patients with clinically significant macular edema (CSME). Methods In this prospective non-comparative interventional case series, sub-tenon's injection of 2.5mg/0.1ml bevacizumab was performed for eyes with CSME. Macular thickness and best corrected visual acuity measurements were performed before and one month after injections. Results Nineteen eyes of twelve patients with a mean age of 59.8±5.7years were evaluated. Thirteen eyes (68.4%) had center-involving macular edema. No significant difference was observed between pre- and post-injection central subfield retinal thickness measurements ( P =0.3). Central subfield thickness measurements improved or remained unchanged in 13 eyes (68.4%). Baseline BCVA of 0.48±0.35 LogMAR improved to 0.36±0.26 LogMAR after injection ( P =0.01). Improvement of>2 lines in BCVA was found in 5 eyes (26.3%), and no eye lost>2 lines of BCVA. No complication associated with sub-tenon's injection was observed. Conclusion Sub-tenon's injection of bevacizumab resulted in significant short-term visual improvement in eyes with CSME. Retinal thickness changes were not significant.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results